CD19-CD34t metabolically programmed CAR transduced T-cells / Medical University of South Carolina - LARVOL DELTA

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: Medical University of South Carolina | Trial primary completion date: Sep 2025 ➔ Nov 2026

Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: Medical University of South Carolina | Not yet recruiting ➔ Recruiting | Phase classification: P1b ➔ P1/2

CAR T-Cell Therapy • Enrollment open • Phase classification • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1b | N=27 | Not yet recruiting | Sponsor: Medical University of South Carolina | Trial completion date: Feb 2026 ➔ Dec 2026 | Initiation date: Apr 2023 ➔ Aug 2023 | Trial primary completion date: Feb 2025 ➔ Aug 2025

CAR T-Cell Therapy • Trial completion date • Trial initiation date • Trial primary completion date • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1b | N=27 | Not yet recruiting | Sponsor: Medical University of South Carolina

CAR T-Cell Therapy • New P1 trial • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19